|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-8-25
|
|
pubmed:abstractText |
Erlotinib is an orally active small-molecule tyrosine kinase inhibitor targeted against human epidermal growth factor receptor 1/epidermal growth factor receptor (ErbB1), known to be overexpressed in a variety of cancers, including prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1624-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18467313-Adenocarcinoma,
pubmed-meshheading:18467313-Administration, Oral,
pubmed-meshheading:18467313-Aged,
pubmed-meshheading:18467313-Dose-Response Relationship, Drug,
pubmed-meshheading:18467313-Drug Administration Schedule,
pubmed-meshheading:18467313-Humans,
pubmed-meshheading:18467313-Kaplan-Meier Estimate,
pubmed-meshheading:18467313-Male,
pubmed-meshheading:18467313-Maximum Tolerated Dose,
pubmed-meshheading:18467313-Middle Aged,
pubmed-meshheading:18467313-Neoplasm Metastasis,
pubmed-meshheading:18467313-Neoplasm Staging,
pubmed-meshheading:18467313-Probability,
pubmed-meshheading:18467313-Prognosis,
pubmed-meshheading:18467313-Prostate-Specific Antigen,
pubmed-meshheading:18467313-Prostatic Neoplasms,
pubmed-meshheading:18467313-Protein Kinase Inhibitors,
pubmed-meshheading:18467313-Quinazolines,
pubmed-meshheading:18467313-Risk Assessment,
pubmed-meshheading:18467313-Survival Analysis,
pubmed-meshheading:18467313-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France. gravisg@marseille.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
